News
-
-
PRESS RELEASE
FDA-Authorized Expanded Access Programs Utilizing Jaguar Health's Novel Crofelemer Powder for Oral Solution to Treat Two Pediatric Intestinal Failure Patients with Microvillus Inclusion Disease
Jaguar Health announces expanded access programs for pediatric patients with microvillus inclusion disease using crofelemer powder. Positive results from initial trials presented -
-
PRESS RELEASE
Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research updates recommendation for Jaguar Health Inc to BUY with a target price of USD 35. Company reports H1/25 results in line with estimates, focuses on securing funding for promising pipeline -
-
PRESS RELEASE
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health receives $250,000 grant from FDA's CVM for Canalevia-CA1 to treat chemotherapy-induced diarrhea in dogs. Company seeks to expand partnership for global commercialization of Canalevia -
-
PRESS RELEASE
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Jaguar Health's Napo Pharmaceuticals submits orphan drug designation application to FDA for crofelemer in treating diarrhea in adult patients with breast cancer metastasized to the brain, targeting expedited regulatory pathways -
-
PRESS RELEASE
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress
